P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...

Bristol Myers Squibb (BMY) has recently stepped into the spotlight, especially with Jefferies upgrading its rating from "Hold" to "Buy." This is a big deal because analysts had been on the fence about ...

From a pig kidney transplant to restoring genetic deafness, 2024 was a year full of medical breakthroughs. The breakthroughs ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely ...

schizophrenia treatment market is expected to expand globally by enhancing existing treatments and improving patient care.

Makary will “restore FDA to the Gold Standard of Scientific Research, and cut the bureaucratic red tape at the Agency to make sure Americans get the Medical Cures and Treatments they deserve ...

We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...

The data analytics and consulting company valued the market at $8.4 billion in 2021. The forecasted 7.4% compound annual ...

As 2024 comes to an end, it is crucial to take a look at some of the major medical advancements that happened this year. 2024 ...

Neurocrine’s Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy ...

There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...